DE2423129A1 - Verfahren zur herstellung temperaturempfindlicher, nicht pathogener mutantenstaemme von rinder-adeno-virusstaemmen und diese virusstaemme enthaltende lebendvakzine - Google Patents
Verfahren zur herstellung temperaturempfindlicher, nicht pathogener mutantenstaemme von rinder-adeno-virusstaemmen und diese virusstaemme enthaltende lebendvakzineInfo
- Publication number
- DE2423129A1 DE2423129A1 DE2423129A DE2423129A DE2423129A1 DE 2423129 A1 DE2423129 A1 DE 2423129A1 DE 2423129 A DE2423129 A DE 2423129A DE 2423129 A DE2423129 A DE 2423129A DE 2423129 A1 DE2423129 A1 DE 2423129A1
- Authority
- DE
- Germany
- Prior art keywords
- bovine
- virus
- temperature
- vaccine
- live
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/235—Adenoviridae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/01—Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10111—Atadenovirus, e.g. ovine adenovirus D
- C12N2710/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/813—Viral vaccine for bovine species, e.g. cattle
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/821—Drug, bio-affecting and body treating compositions involving temperature-sensitive mutant virus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Description
Stamm WBR 1/7 Eunice |
Virusausbeute TCIDc0 (ausgedrückt in Iog10/0,1 ml) bei |
39,50C | Unterschied zwischen 39,5°C und 35°C |
35°C | 6,5 1,7 |
O 2,8 |
|
6,5 |
Passage 1 k 7 |
Virustiter TCID,_0, ausgedrückt in Iog10/O,1 mi, |
"bei unerlaubter Tem peratur (39,5°C) |
"bei erlaubter Tem peratur (3O-35°C) |
0,5 1.5 |
|
5 6,25 6,3 |
Titer (log 0 TCID /0,1 ml bei erlaubten und uner laubten Temperaturen) des Virus, das bei 39»5 C ' hergestellt vurde |
Titer |
Inkubationstemperatur der' Virus-Titration |
3 |
35°C 39,5°C |
Num mer des |
Tierstatus | Tag der Rückisolierung nacti der Impfung |
3 | k | 5 | 6 | 7 | 10 | 11 |
Tie res |
— | — | _ | — | — | — | — | ||
70 | indirekte Kontrolle | - | - | - | - | - | - | ||
72 | Il - Il | - | - | - | - | - | - | ||
71 | direkte Kontrolle | - | - | - | - | -. - | - | ||
73 | Il It | - | - | + · | - | - | - | ||
lh | geimpft | - | - | - | - | - | - | - | |
75 | H | + | + | - | + | - | - | - | |
76 | Il | ( + ) | - | - | - | - | - | - | |
77 | ti | - | + | - | + | - | - | - | |
78 | It | - | + | - - | - | - | - | - | |
79 | Il | ( + ) | - | - | - | - | - | - | |
80 | Il | + | ( + ) | - | - | - | - | ||
81 | Il | + | + | + | — | — | — | ||
82 |
Il
- |
diese Kulturen vor dem Beimpfen gewaschen werden, um restliches Rinderserum auszuschließen. Für jede Verdünnung werden 4 bis 5 Röhrchen mit 0,1 ml beimpft. Die Kulturen werden bei 35°C inkubiert und die Titer durch Schätzung des cytopathogenen Effektes nach einer Inkubationszeit von 14 Tagen bestimmt.
aus der Nase der geimpften Tiere wiederisolierten Vakzinevirus-Eunice-Stammes nach in vivo-Passage hervor.
lh | Tag der | Vi | Tabelle V | °C | ml | ) ' | °C | 38,5°C | in | 39 | ,50C | |
76 | Wieder- | 75 | Temperatur von: | 7 5 | 3,25 | Dex einer | 40 | ,5 | ||||
78 | isolie— | 75 | 38 | 75 | 3,5 | S° | ,5 | |||||
82 | nach der Impfung |
VJl | ' 3, | 25 | 3,25 | 39°C | ,5 | |||||
/7 | 5 | ,75 | h, | ,25. | 14,25 | 2,25 | £° | ,5 | ||||
Eunice | 6 | ,25 | 3', | ,75 | 5 - | 2,75 | .5 | ,25 | ||||
6 | rustiter TCID n (ausgedrückt | ,25 | k | ,50 | nb | 2,5 | 1 | ,5 | ||||
6 | login/0,1 | k | 3,25 | |||||||||
- | 5 | 5 | ||||||||||
Virus ur- sprung |
— | 35 | nb | |||||||||
Tief | 3, | |||||||||||
Tier | ||||||||||||
Tier | 3 | |||||||||||
Tier | U | |||||||||||
WBR 1 | U | |||||||||||
5 | ||||||||||||
Nummer des Tieres |
Tierstatus | Tag der Wiederisolierung nach der .Belastungs infektion |
3 | + | 6 | 7 | 10 |
TO | indir. Kontr. | + | + | + | — | ||
T2 | It Il | . + | - | - | ■ - | + | |
71 | direkte Kontr. | + | - | - | - - | - | |
73 | η Ii | + . | - | - | -- | + | |
Ik | geimpft | - | - | - | - | - | |
75 | It | - | - | - | - | - | |
76 | - Il | - | - | - | - | - | |
77 | Il | -( + ) | - | - | - | - | |
78 | It | - | - | - | - | - | |
' 79 | Il | - | - | - | - | - | |
80 | II | - | - | - | - | - | |
81 | II | - | — | - | - | - | |
" 82 | Il | + | — | — | — | ||
1 Stunde bei 35°C zusammengebracht, bevor es in die Kulturröhrchen (0,2 ml/Gefäß) verteilt wird. Es werden 4 Röhrchen für jede Serumverdünnung verwendet. Die beimpften Röhrchen
werden bei 35°C inkubiert und die Serumtiter nach einer Inkubationszeit von 14 Tagen bestimmt.
VII zusammengestellt, in denen der Titer als reziproker Wert der höchsten Verdünnung, bei der 50 Prozent der Röhrchen
völlig neutralisiert waren, ausgedrückt ist.
Num | Tierstatus | Virustiter . . | 13 | 27 Infek- tions- : datum |
*2(15 Tage lach dem Cnfektions- latum) |
mer | <8 | <k | 16 | ||
des • Tie |
indir.Kontrolle | 6k | 256 | ||
res | Il It | Tag der Probenentnahme nach dein Impf t ap; |
128 | $256 | 512 |
70 | direkte Kontr. | 128 | 128 | 102I1 | |
72 | Il Il | k | $256 | 512 | 512 |
71 | geimpft | 6k | S256 | »102U | >2OU8 |
73 | Il | 128 | $256 | 512 | 102^ |
lh | Il | *128 | $256 | 256 | 256 |
75 | Il | 32 | >256 | 256 | 256 |
76 | Il | 128 | ?256 | S1.02lt | 20^8 |
77 | Il | 32 | *256 | 512 | 512 . |
78 | Il | »128 | S256 | 256 | 20U8 |
79 | Il | 32 | 128 | 128 | 128 |
•80 | Il | 32 | |||
81 | 16 | ||||
82 | $"128 | ||||
8 | |||||
indem die Nasenhöhlen mit ^O ml 1n Salzlösung/Nasenloch gewaschen werden. Die Waschlösungeri werden dann beschallt und dann durch Ultrafiltration auf 1/10 ihres ursprünglichen
Volumens konzentriert.
Num | Tierstatus | Neutralisationsindex | -1 | 11 | 17 | 27 |
mer | 1 | 0 | 1 | 1 | ||
des | 0 | 0 | nb | nb | ||
Tie | indir.Kontrolle | Tage der Probeentnahme nach dem | 3 | 0 | 0 | 0 |
res | Il It | ImöftacT | 0 | 0 | 0 | 0 |
TO | direkte Kontr. | 0 | * 3 |
3 | 3 | |
72 | It It | 1 | >k | >k | >h | |
71 | geimpft | 0 | 2 | : nb | 2 | |
73 | I! | 0 | 3 | 3 | 0 | |
lh | Il | 0 | 1 | 1 | 2 | |
75 | Il | 0 | 3 | 3 | 1 | |
76 | Il | 0 | 3 | 1 | 2 | |
77 | Il | 0 | 3 | nb | 3 | |
"78 | Il | 0 | 1 | 1 | 0 | |
79 | It | |||||
80 | Il | |||||
81 | ||||||
82 | ||||||
eines geimpft wurde, festgestellt. Lediglich das geimpfte
Tier Nr. 75 zeigte einen wesentlichen Anstieg des Neutralisationsindexes 11 Tage nach der Impfung.
1-Virus und Rinder-Adeno-3-Virus durchgeführt. Die Ergebnisse sind in Tabelle IX zusammengefaßt.
Num mer |
Tierstatus | Neutralisationsindex der Proben nach Impjfung |
Rinder- Adeno—1- Virus |
des Tie res |
direkte Kontrolle | Rinder- Adeno~3-Vi rus |
0 |
71 | Il Il | 0 | 0 |
73 | geimpft | 0 | 0 |
lh | Il | 2 | 0 |
75 | Il | >u ■ . | 0 |
77 | Il | 3 | 0 |
79 | Il | 3 | 0 |
80 | Il | . 2 | 0 |
81 | Il | 3 | 0 |
82 | 1 |
Num mer des Tie res |
Serologische Reaktion, ausgedrückt in | nach der Imp fung |
vor • der Imp fung |
nach der Imp fung |
Haemagglutina- tions-Hemmungsti- ter für PI^5-Virus |
nach der Imp fung |
1 2 3 Ii |
Seroneutralisätions-Ariti- körpertiter für Adeno-3-Virus IBR-Virus |
1'6 32 32 6k |
O O O O | 2 2 8 1 |
vor der Imp fung |
128 32 128 32 |
vor der Imp fung |
<8 8 . <8 32 |
|||||
< h <16 " '■< k 8 |
Num | Tierstatus | vakziniert | Serologische Reaktion, | ausge- | • | <8 | 6k | - | 16 | 21 | ■ | 32 |
mer | 10 »25 TCID | drückt als Seroneutralisations- | nach dem | |||||||||
des | Direkt | verdünnungstitei | 16 | |||||||||
Tie | kontrolle | <8 | 6k | 32 | ||||||||
res | 0 Ak | 6k | ||||||||||
vakziniert | Tage der Probeentnahme | <8 | 16 | 16 | 32 | |||||||
ς 25 | ImDf tae: | |||||||||||
636 | 10 » TCID50 | 6k | 32 | |||||||||
vakziniert | 8 | 32 | ||||||||||
To^25 TCID50 | 16 | |||||||||||
6k6 | vakziniert | <8 | ||||||||||
ιοί·25 TCTD 50 |
||||||||||||
6kl | vakziniert | |||||||||||
mit | 16 | |||||||||||
1*97 | 10 ' ^ TCID | |||||||||||
vakziniert | 16 ■ | |||||||||||
10 t>2^ TCID,.„ | ||||||||||||
50lf | 50 | |||||||||||
635 | ||||||||||||
510 | ||||||||||||
Claims (14)
ratur von 39 bis 40 C isoliert.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36021973A | 1973-05-14 | 1973-05-14 | |
US05438503 US3927208A (en) | 1973-05-14 | 1974-01-31 | Live bovine adenovirus vaccines, preparation thereof and method of vaccination using them |
Publications (2)
Publication Number | Publication Date |
---|---|
DE2423129A1 true DE2423129A1 (de) | 1974-12-05 |
DE2423129C2 DE2423129C2 (de) | 1985-01-10 |
Family
ID=27000811
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE2463143A Expired DE2463143C2 (de) | 1973-05-14 | 1974-05-13 | Polyvalente Rindervirus-Lebendimpfstoffe |
DE2423129A Expired DE2423129C2 (de) | 1973-05-14 | 1974-05-13 | Temperaturempfindliche, nicht-pathogene Rinder-Adeno-Virus-Mutantenstämme, Verfahren zu ihrer Herstellung und diese Virusstämme enthaltender Lebendimpfstoff |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE2463143A Expired DE2463143C2 (de) | 1973-05-14 | 1974-05-13 | Polyvalente Rindervirus-Lebendimpfstoffe |
Country Status (13)
Country | Link |
---|---|
US (1) | US3927208A (de) |
JP (1) | JPS5710845B2 (de) |
AR (1) | AR203646A1 (de) |
CA (1) | CA1039186A (de) |
CH (1) | CH589141A5 (de) |
DD (1) | DD112663A5 (de) |
DE (2) | DE2463143C2 (de) |
ES (1) | ES426215A1 (de) |
FR (1) | FR2229398B1 (de) |
GB (1) | GB1430711A (de) |
HU (1) | HU169758B (de) |
IE (1) | IE40924B1 (de) |
NL (1) | NL7406407A (de) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4225582A (en) * | 1979-03-08 | 1980-09-30 | The University Of Illinois Foundation | Vaccine for equine rhinopneumonitis |
US4618493A (en) * | 1982-10-13 | 1986-10-21 | Smithkline-Rit | Temperature sensitive strains of bovine viral diarrhoea virus, preparation thereof and vaccines containing them |
NZ224422A (en) * | 1987-05-05 | 1990-11-27 | Molecular Eng Ass | Composition adapted for intranasal immunisation against viral infection comprising a glycoprotein complexed with a lipid |
US4867975A (en) * | 1988-01-27 | 1989-09-19 | University Of Delaware | Live attenuated temperature-sensitive avian infectious bronchitis virus vaccines and preparation and use thereof |
US7678087B2 (en) * | 1999-09-29 | 2010-03-16 | Heska Corporation | Equine intranasal delivery system |
US6398774B1 (en) | 1999-09-29 | 2002-06-04 | Heska Corporation | Intranasal delivery system |
EP2552478B1 (de) * | 2010-03-31 | 2016-12-21 | Stabilitech Ltd. | Hilfsstoffe zur stabilisierung von viralen partikeln |
JP5960120B2 (ja) | 2010-03-31 | 2016-08-02 | スタビリテック リミテッド | ウイルス粒子の安定化 |
GB2499480A (en) | 2010-03-31 | 2013-08-21 | Stabilitech Ltd | Method for preserving alum adjuvants and alum-adjuvanted vaccines |
GB201117233D0 (en) | 2011-10-05 | 2011-11-16 | Stabilitech Ltd | Stabilisation of polypeptides |
GB201406569D0 (en) | 2014-04-11 | 2014-05-28 | Stabilitech Ltd | Vaccine compositions |
GB2562241B (en) | 2017-05-08 | 2022-04-06 | Stabilitech Biopharma Ltd | Vaccine compositions |
US10581081B1 (en) * | 2019-02-01 | 2020-03-03 | Chang Chun Petrochemical Co., Ltd. | Copper foil for negative electrode current collector of lithium ion secondary battery |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3052606A (en) * | 1958-08-30 | 1962-09-04 | Behringwerke Ag | Viral mutation with nitrites |
-
1974
- 1974-01-31 US US05438503 patent/US3927208A/en not_active Expired - Lifetime
- 1974-04-24 FR FR7414220A patent/FR2229398B1/fr not_active Expired
- 1974-04-25 CH CH570074A patent/CH589141A5/xx not_active IP Right Cessation
- 1974-05-10 IE IE1001/74A patent/IE40924B1/xx unknown
- 1974-05-11 ES ES426215A patent/ES426215A1/es not_active Expired
- 1974-05-13 DE DE2463143A patent/DE2463143C2/de not_active Expired
- 1974-05-13 JP JP5376774A patent/JPS5710845B2/ja not_active Expired
- 1974-05-13 CA CA199,628A patent/CA1039186A/en not_active Expired
- 1974-05-13 DE DE2423129A patent/DE2423129C2/de not_active Expired
- 1974-05-13 NL NL7406407A patent/NL7406407A/xx not_active Application Discontinuation
- 1974-05-14 GB GB2124874A patent/GB1430711A/en not_active Expired
- 1974-05-14 AR AR25373674A patent/AR203646A1/es active
- 1974-05-14 DD DD17849674A patent/DD112663A5/xx unknown
- 1974-05-14 HU HURE000551 patent/HU169758B/hu unknown
Non-Patent Citations (3)
Title |
---|
Chem.Abstr., 1971, S. 154, Ref. 60236q * |
Chem.Abstr., 1972, S. 216, Ref. 137264y * |
Mayr et. al: Virologische Arbeitsmethoden, Stuttgart 1974, S.263 u. 266 |
Also Published As
Publication number | Publication date |
---|---|
AR203646A1 (es) | 1975-09-30 |
JPS5052226A (de) | 1975-05-09 |
ES426215A1 (es) | 1976-11-16 |
GB1430711A (en) | 1976-04-07 |
JPS5710845B2 (de) | 1982-03-01 |
DE2423129C2 (de) | 1985-01-10 |
CA1039186A (en) | 1978-09-26 |
US3927208A (en) | 1975-12-16 |
IE40924L (en) | 1974-11-14 |
AU6888474A (en) | 1975-11-13 |
DD112663A5 (de) | 1975-04-20 |
HU169758B (de) | 1977-02-28 |
IE40924B1 (en) | 1979-09-12 |
NL7406407A (de) | 1974-11-18 |
CH589141A5 (de) | 1977-06-30 |
FR2229398B1 (de) | 1978-03-24 |
DE2463143C2 (de) | 1985-04-11 |
FR2229398A1 (de) | 1974-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AT407958B (de) | Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation | |
IE53872B1 (en) | Infectious-bronchitis vaccines for poultry, combined infectious-bronchitis vaccines, process for preparing such vaccines, process for preventing infectious bronchitis and infectious-bronchitis virus strain | |
DE3882599T2 (de) | Hundecoronavirus-Impfstoff. | |
DE2423129C2 (de) | Temperaturempfindliche, nicht-pathogene Rinder-Adeno-Virus-Mutantenstämme, Verfahren zu ihrer Herstellung und diese Virusstämme enthaltender Lebendimpfstoff | |
DE3889138T2 (de) | Influenza-Impfstoff. | |
DE69923470T2 (de) | Kombinationsimpfstoff gegen hav und masernvirus und verfahren zu seiner produktion | |
DE2708668A1 (de) | Nd-impfstoff und verfahren zu seiner herstellung | |
US3962424A (en) | Live brovine adenovirus vaccines, preparation thereof and method of vaccination using them | |
DE2362067C2 (de) | Temperaturempfindliche, nicht-pathogene, infektiöse Rinder-Rhinotracheitis-Virusstämme, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Lebendimpfstoffen | |
DE1617940A1 (de) | Zellstaemme | |
DE2817891A1 (de) | Nd-impfstoff und verfahren zu seiner herstellung | |
EP0030063A2 (de) | Impfstoffe für infektiöse Bronchitis bei Geflügel, kombinierte Impfstoffe für infektiöse Bronchitis, Verfahren zur Herstellung solcher Impfstoffe, Verfahren zur Verhütung infektiöser Bronchitis und Virusstämme der infektiösen Bronchitis | |
DE2323847C3 (de) | Lebendimpfstoff zur Immunisierung von Rindern gegen die Parainfluenza-3-Virus-Infektion | |
DE2553998C2 (de) | Mumpsvaccin und Verfahren zu seiner Herstellung | |
DE1198489B (de) | Verfahren zur Herstellung eines Impfstoffes gegen Panleucopenie | |
DE2538994A1 (de) | Bakterieller impfstoff und verfahren zu seiner herstellung | |
DE2445819A1 (de) | Verfahren zur herstellung stabiler, gegen seruminhibitoren resistenter h tief 3 n tief 2 -influenzavirusstaemme und diese virusstaemme enthaltende vakzinen | |
CH616959A5 (de) | ||
DE2415353C2 (de) | ||
DE2739439C2 (de) | ||
DE2225548C3 (de) | Intravenös verträglicher Impfstoff gegen Staupe- und Hepatite contagiosa canis | |
EP0491125B1 (de) | Impfstoffe gegen equine Herpesviren und ihre Herstellung | |
IE48482B1 (en) | Combined vaccine active against newcastle disease and egg production drop caused by adeno-like viruses,process for preparing it,adeno-like and newcastle disease virus strains | |
Greenbaum et al. | EXPERIMENTAL STUDIES ON IMMUNITY IN HERPES SIMPLEX: WITH NOTES ON THE INFECTIVITY OF THE BLOOD AND SPINAL FLUID AND ON THE FILTRABILITY OF THE HERPETIC VIRUS | |
DE3005495C2 (de) | Herstellung von Fragmenten von Viren mit Lipidhülle und sie enthaltende Arzneimittelzubereitungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
OD | Request for examination | ||
OGA | New person/name/address of the applicant | ||
8172 | Supplementary division/partition in: |
Ref country code: DE Ref document number: 2463143 Format of ref document f/p: P |
|
AH | Division in |
Ref country code: DE Ref document number: 2463143 Format of ref document f/p: P |
|
Q171 | Divided out to: |
Ref country code: DE Ref document number: 2463143 |
|
D2 | Grant after examination | ||
AH | Division in |
Ref country code: DE Ref document number: 2463143 Format of ref document f/p: P |
|
8364 | No opposition during term of opposition | ||
8327 | Change in the person/name/address of the patent owner |
Owner name: SMITHKLINE BECKMAN - ANIMAL HEALTH PRODUCTS S.A., |
|
8328 | Change in the person/name/address of the agent |
Free format text: VOSSIUS, V., DIPL.-CHEM. DR.RER.NAT. TAUCHNER, P., DIPL.-CHEM. DR.RER.NAT. HEUNEMANN, D., DIPL.-PHYS. DR.RER.NAT. RAUH, P., DIPL.-CHEM. DR.RER.NAT. HERMANN, G., DIPL.-PHYS. DR.RER.NAT. SCHMIDT, J., DIPL.-ING. JAENICHEN, H., DIPL.-BIOL. DR.RER.NAT., PAT.-ANWAELTE, 8000 MUENCHEN |